论文部分内容阅读
肿瘤放疗平均治愈率仅40％,其原因为肿瘤组织中约占10％的乏氧细胞的存在,它们对射线不敏感而成为放疗后再生长的根源。乏氧细胞放射增敏剂的研究已取得进展。属于模拟氧作用的亲电子增敏剂,例如硝基咪唑类的Misonidazole(MISO),Etanidaz-ole(SR-2508),P imonidazole(Ro-03-8799)先后进入临床研究,MISO的神经毒性限制了它的应用。另一类增敏剂以BSO为代表。BSO化学名为S-正丁基高胱氨酸亚磺酰亚胺(s-n-butyl homocysreine
The average cure rate of tumor radiotherapy is only 40% because of the existence of about 10% of hypoxic cells in tumor tissue, which are insensitive to radiotherapy and become the source of regrowth after radiotherapy. Research on hypoxic cell radiosensitizer has made progress. Electrophilic sensitizers belonging to the mimic oxygen action, such as nitroimidazoles such as Misonidazole (MISO), Etanidazole (SR-2508) and Pidotimeazole (Ro-03-8799), have entered clinical studies successively. The neurotoxicity limits of MISO Its application. Another type of sensitizer is represented by BSO. BSO chemical name is S-n-butyl homocystine sulfoximine (s-n-butyl homocysreine